ChiCTR1900024611
正在进行
洛匹那韦利托那韦片+拉米夫定
/
洛匹那韦利托那韦片+拉米夫定
2019-07-18
/
/
AIDS
克立芝联合拉米夫定简化方案对HIV感染者初始治疗的疗效及安全性研究
克立芝联合拉米夫定简化方案对HIV感染者初始治疗的疗效及安全性研究
To understand the effectiveness and security of dual therapy with boosted protease inhibitors (bPI) and lamivudine (3TC) compared with EFV-based triple therapy in HIV patients.
随机平行对照
其它
Randomization was stratified sampling according to the screening level of plasma HIV-1 RNA (≤ 100,000 vs. > 100,000 copies/ml). Patients were randomly assigned (1:1) via a computer-generated allocation schedule to receive dual therapy or triple therapy.
No
无
/
100
/
2015-01-01
2019-06-30
/
1. HIV-1 infected ART-native patients; 2. at least 18 years old; 3. plasma HIV-1 RNA level of more than 1000 copies/ml and CD4+ cell count over 200 cells/mm3.；
登录查看1. Patients who were pregnant or breastfeeding; 2. co-infected with HBV or HCV; 3. had chronic liver disease, or had active AIDS-associated opportunistic diseases within 30 days after screening; 4. had poor adherence.；
登录查看广州市第八人民医院
/
精准药物2024-11-22
亚泰制药2024-11-22
医药时间2024-11-21
一度医药2024-11-21
新药创始人2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
药时空2024-11-21
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
